J
Jay H. Kleiman
Researcher at Pharmacia
Publications - 14
Citations - 5151
Jay H. Kleiman is an academic researcher from Pharmacia. The author has contributed to research in topics: Eplerenone & Aldosterone. The author has an hindex of 9, co-authored 14 publications receiving 4908 citations. Previous affiliations of Jay H. Kleiman include University of Wisconsin-Madison & National Cheng Kung University.
Papers
More filters
Journal ArticleDOI
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt,Willem J. Remme,Faiez Zannad,James D. Neaton,Felipe Martinez,Barbara Roniker,Richard Bittman,Steve Hurley,Jay H. Kleiman,Marjorie Gatlin +9 more
TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI
The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction
Bertram Pitt,Bertram Pitt,Bertram Pitt,Gordon H. Williams,Gordon H. Williams,Gordon H. Williams,Willem Remme,Willem Remme,Willem Remme,Felipe Martinez,Felipe Martinez,Felipe Martinez,Jose Lopez-Sendon,Jose Lopez-Sendon,Jose Lopez-Sendon,Faiez Zannad,Faiez Zannad,Faiez Zannad,James D. Neaton,James D. Neaton,James D. Neaton,Barbara Roniker,Barbara Roniker,Barbara Roniker,Steve Hurley,Steve Hurley,Steve Hurley,Dan Burns,Dan Burns,Dan Burns,Richard Bittman,Richard Bittman,Richard Bittman,Jay H. Kleiman,Jay H. Kleiman,Jay H. Kleiman +35 more
TL;DR: If the hypothesis being tested in the EPHESUS trial proves correct, eplerenone has the potential to be used in a broad population to prevent progressive left ventricular remodeling, ventricular fibrosis, malignant arrhythmias, non-fatal AMI, and sudden cardiac death.
Journal ArticleDOI
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
John M. Flack,Suzanne Oparil,J. Howard Pratt,Barbara Roniker,Susan M. Garthwaite,Jay H. Kleiman,Yonghong Yang,Scott Krause,Diane Workman,Elijah Saunders +9 more
TL;DR: Eplerenone was as effective in reducing SBP and DBP in the high renin patient, but more effective than losartan in the low renin patients, and was superior to placebo in white patients.
Journal ArticleDOI
OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria
Murray Epstein,V. Buckalew,F. Martinez,J. Altamirano,Barbara Roniker,Jay H. Kleiman,Scott Krause +6 more
Journal ArticleDOI
Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension
Ellen Burgess,Yves Lacourcière,Luis M. Ruilope-Urioste,Suzanne Oparil,Jay H. Kleiman,Scott Krause,Barbara Roniker,Clement J. Maurath +7 more
TL;DR: Eplerenone therapy was effective in the treatment of mild to moderate hypertension over a 14-month period, either as monotherapy or in combination with another antihypertensive agent.